Pangea Biomed

Video #2 of our short video series is about the technology behind ENLIGHT. How exactly does our ENLIGHT platform work? Watch to learn how we match the right treatment to the right patients. CC: Tuvik Beker Ranit Aharonov Emmanuel Elalouf #precisiononology #cancer

Our partnership with Sharett Oncology Institute and HCRI HADASSAH CANCER RESEARCH INSTITUTE, and Ultima Genomics was featured in Precision Medicine Online. Together, we aim to enhance the accuracy and effectiveness of solid tumor cancer treatment predictions through advanced genetic and transcriptomic profiling. Read the full article by Catherine Shaffer here: https://bit.ly/3Z0jMAP #PrecisionOncology #CancerResearch #AIinHealthcare #GenomicSequencing

🚀 We're teaming up with the Sharett Oncology Institute and HCRI HADASSAH CANCER RESEARCH INSTITUTE at the Hadassah University Hospital Ein-Kerem, and Ultima Genomics, to make more precise and personalized treatment decisions for solid tumor patients.    Solid tumors represent almost 90% of adult human cancers but are challenging to treat due to their genetic heterogeneity and potential to metastasize. Our ENLIGHT platform will combine comprehensive DNA, RNA, and imaging data from Hadassah and Ultima Genomics to deliver insights that are expected to improve patients' treatment choices. Once fully deployed, this initiative is expected to impact over 2,000 patients annually. Learn more here: https://lnkd.in/dPZuQDh7 #PrecisionOncology #CancerResearch #AIinHealthcare #GenomicSequencing

Becoming an octogenarian (80 - 89 years old) might decrease the risk of lung cancer. In a recent study, researchers at Stanford University and Memorial Sloan Kettering Cancer Center showed that increased production of the protein NUPR1 in older lungs affects iron metabolism, limiting rapid cancer growth.   Learn more via Nature Portfolio: https://lnkd.in/er7hwCp9 #personalizedmedicine #pangeabiomed #precisiononcology 

Researchers at Sunnybrook Health Sciences Centre and the University of Toronto are shining a light on a cancer treatment known as radioligand therapy (RLT). This type of therapy has been shown to significantly reduce the risk of progression and death in patients with advanced neuroendocrine tumors. Learn more about the study and personalized cancer therapy via Medical Xpress: https://lnkd.in/g-qFtyS3 #personalizedmedicine #pangeabiomed #precisiononcology 

Our latest findings establishing the efficacy of our ENLIGHT-DP platform have been published in Nature Cancer (Springer Nature Group). The study, conducted in collaboration with researchers from The Australian National University and from the National Cancer Institute (NCI), reveals that combining ENLIGHT with the DeepPT approach for inferring gene expression from hematoxylin and eosin stain slide scans significantly advanced the ability to predict therapeutic responses across multiple cancer types and drugs from histopathology images. Learn more via Jonathan D. Grinstein, PhD for Inside Precision Medicine: https://lnkd.in/gkQMK9Vd or access the full paper at https://rdcu.be/dMB0u CC: Tuvik Beker Ranit Aharonov Eytan Ruppin Kenneth Aldape James Gulley MD PhD FACP Carlos Caldas Sharon Pine Adam Sowalsky Scott Wilkinson Peng Jiang Jason Redman Clint Allen Shania Bailey Julius Strauss Wiem Lassoued Tejas Patil Chani Stossel Chris Dampier Neelam Sinha Sanju Sinha Stephen John Sammut Katherine Caley Efrat Elis Doreen S. Ben-Zvi, Ph.D Leandro Hermida Eldad Shulman Gal Dinstag Danh-Tai Hoang, PhD @Eric A. Stone @Talia Golan @Arun Rajan #precisiononcology #personalizedmedicine #pangeabiomed #naturecancer

A recent study by Yale Cancer Center and Yale School of Medicine revealed that combining chemotherapy before and after surgery extends survival rates for pancreatic cancer patients, emphasizing how changing just one element in a traditional treatment plan can impact results. Learn more from Medical Xpress: https://bit.ly/3xHzuVX  At Pangea, we're committed to supporting research that enhances patient outcomes. Through our ENLIGHT platform we can uncover many more clinically relevant insights than approaches based solely on genomic alterations: #precisiononcology #personalizedmedicine #pangeabiomed 

“I am cognizant that every FDA treatment we have for pancreatic cancer began as a clinical trial,” said 12-year pancreatic cancer survivor, Steven Merlin. “I am grateful to those who participated in clinical trials to make it possible.” Pancreatic cancer is one of the harshest forms of cancer, with a 5-year survival rate of just 3% for those diagnosed after it has spread. Steven Merlin’s story highlights how personalized medicine can lead to remarkable outcomes. Read about Steven’s cancer treatment experience and how he and his healthcare team beat the odds via Erin Post at  Pancreatic Cancer Action Network: https://lnkd.in/gBbpTf-9 #precisiononcology #personalizedmedicine #pangeabiomed 

We were honored to participate in the American Society of Clinical Oncology (ASCO) Annual Meeting, the Biotechnology Innovation Organization (BIO) International Convention and European Association for Cancer Research (EACR)) Conference. Our team, including CTO Ranit Aharonov, COO Emmanuel Elalouf, Head of Research Gal Dinstag, and Researcher Omer Tirosh proudly represented our work in the oncology space, specifically our ENLIGHT platform. The team also introduced SCOT – a novel method for testing predictive biomarkers before interventional clinical data is available. These events provided invaluable opportunities to connect with other leaders in oncology and biotechnology, showcase our research, and explore new collaborations. We’ve included some of our favorite photos from the events! Didn’t get a chance to attend and would like to learn more? DM us or email [email protected] #ASCO24 #BIO2024  #EACR24

We are starting a new short video series that dives into the power of ENLIGHT. 🚀 20 million people are diagnosed with cancer each year. Learn more in our first video on how ENLIGHT leverages precision oncology to bring treatment to more patients. Watch here ⬇️ #precisiononcology #cancer